eclipse - a randomized phase 3 trial for 177-lu-psma-i&t in patients with mcrpc
Published 1 year ago • 3.7K plays • Length 2:24Download video MP4
Download video MP3
Similar videos
-
4:48
vision: lu-177-psma-617 in mcrpc
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
7:14
vision study
-
11:07
phase 3 vision study of 177lupsma 617 for metastatic castration-resistant prostate cancer
-
6:24
phase iii study of lutetium-177-psma-617 in patients with metastatic castration-resistant prosta...
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
2:46
upfrontpsma trial: 177lu-psma-617 and docetaxel in mhnpc
-
14:37
lupsma: the newest treatment class for advanced prostate cancer
-
3:01
preliminary findings in mcrpc for fractionated dose 177lu-psma-617
-
1:17
prince: 177lu-psma-617 and pembrolizumab in prostate cancer
-
3:30
how to administer the investigational radiopharmaceutical 177lu-psma-i&t
-
11:23
therap study: lu-psma vs. cabazitaxel #asco20 #anzup
-
4:08
lu-177 psma-617 versus vs cabazitaxel: therap trial @ snmmi 2021
-
![upfront [177lu]lu-psma-617 radioligand therapy prior to radical prostatectomy in men with hr pc](https://i.ytimg.com/vi/BgbkDD3Orew/mqdefault.jpg)
4:28
upfront [177lu]lu-psma-617 radioligand therapy prior to radical prostatectomy in men with hr pc
-
3:36
the palliative benefits of lutetium-177-psma
-
3:17
safety and efficacy of 177lu-psma-617
-
3:16
updated therap data further support lupsma for mcrpc | michael hofman
-
1:34
lu-psma-617 deployment and future of prostate cancer treatment